==== Front PLoS One PLoS One plos PLOS ONE 1932-6203 Public Library of Science San Francisco, CA USA 10.1371/journal.pone.0286854 PONE-D-23-00605 Research Article Medicine and Health Sciences Hematology Anemia Medicine and Health Sciences Nephrology Renal Diseases Chronic Kidney Disease Biology and Life Sciences Anatomy Renal System Kidneys Medicine and Health Sciences Anatomy Renal System Kidneys Biology and Life Sciences Immunology Immune Response Inflammation Medicine and Health Sciences Immunology Immune Response Inflammation Medicine and Health Sciences Clinical Medicine Signs and Symptoms Inflammation Medicine and Health Sciences Endocrinology Endocrine Disorders Diabetes Mellitus Medicine and Health Sciences Medical Conditions Metabolic Disorders Diabetes Mellitus Medicine and Health Sciences Diagnostic Medicine Clinical Laboratory Sciences Transfusion Medicine Blood Transfusion Medicine and Health Sciences Hematology Transfusion Medicine Blood Transfusion Medicine and Health Sciences Nephrology Biology and Life Sciences Biochemistry Hormones Peptide Hormones Erythropoietin A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease Expanded period anemia-related soluble Fas https://orcid.org/0000-0002-7538-477X Andrade Jessica Felício Conceptualization Data curation Formal analysis Investigation Supervision Writing – original draft 1 ¤a ‡ * Dalboni Maria A. Conceptualization Data curation Supervision 2 Clemente Otavio Candido Data curation Formal analysis 1 ¤a Silva Beatriz Moreira Data curation Formal analysis 1 ¤a Domingues Barbara Formaggio Data curation Formal analysis 1 ¤a Rodrigues Adelson Marcal Data curation Formal analysis 1 ¤a Canziani Maria Eugenia Data curation Formal analysis Supervision Writing – original draft 1 ¤a Zarjou Abolfazl Supervision Writing – original draft 3 ‡ Cendoroglo Miguel Supervision Writing – original draft 4 ‡ Goes Miguel Angelo Conceptualization Data curation Formal analysis Supervision Writing – original draft 1 5 ¤a ¤b ‡ 1 Division of Nephrology, Federal University of São Paulo, São Paulo, Brazil 2 Department of Research and Graduate, Universidade Nove de Julho/UNINOVE, São Paulo, Brazil 3 Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America 4 Department of Superintendence and Board, Hospital Israelita Albert Einstein, São Paulo, Brazil 5 Medical School, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil Kannan Lakshmi Editor Pikeville Medical Center, UNITED STATES Competing Interests: The authors have declared that no competing interests exist. ¤a Current address: Department of Nephrology, Federal University of São Paulo, São Paulo, Brazil ¤b Current address: Medical School, Hospital Israelita Albert Einstein, São Paulo, Brazil ‡ JFA, AZ, MC and MAG also contributed equally to this work. * E-mail: andradeljj@yahoo.com 30 6 2023 2023 18 6 e02868548 1 2023 24 5 2023 © 2023 Andrade et al 2023 Andrade et al https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background Anemia is common in chronic kidney disease (CKD) and is associated with outcomes. In addition, serum soluble Fas (sFas) levels are related to anemia and erythropoietin (EPO) resistance. Objectives Firstly, to compare clinical data and serum levels of sFas, EPO, and pro-inflammatory markers between patients with non-dialytic CKD (NDD-CKD) and healthy subjects. Subsequently, to compare and evaluate the relationship of serum EPO, sFas levels with anemia, and outcomes in patients with NDD-CKD over a long follow-up period. Methods We performed a retrospective study in 58 NDD-CKD patients compared with 20 healthy subjects on complete blood count, kidney function, serum EPO, sFas, and inflammatory markers (CRP, IL- 6, and IFN-γ) at baseline. We then compared the same baseline data between patients with NDD-CKD who evolved to anemia and those who did not have anemia over the follow-up. We also evaluated the frequency of outcomes in patients with CKD with higher sFas levels. Finally, we performed a multivariate analysis of factors associated with CKD anemia. Results There were lower eGFR and Hb but higher serum inflammatory markers, sFas levels, sFas/eGFR, and EPO/Hb ratios in patients with NDD-CKD. Comparatively, on the other hand, NDD-CKD patients with anemia had lower eGFR but were older, had more diabetes, and had higher sFas/ eGFR, EPO/Hb ratios, and serum levels of IL-6 and sFas than NDD-CKD without anemia for an extended period. In addition, there was an association in a multivariate analysis of diabetes, age, and sFas levels with kidney anemia. Furthermore, there were higher frequencies of outcomes in increased serum sFas levels. Conclusion As an elective risk factor, serum sFas levels, in addition to age and diabetes, were independently associated with kidney anemia for an extended period. Thus, more studies are necessary to analyze the proper relationship of sFas with kidney anemia and its outcomes and therapy in CKD. The authors received no funding for this work. Data AvailabilityAll data compiled from the results in excel format files are available from the figshare database (DOI: 10.6084/m9.figshare.21619329). Data Availability All data compiled from the results in excel format files are available from the figshare database (DOI: 10.6084/m9.figshare.21619329). ==== Body pmcIntroduction Anemia is a common complication of chronic kidney disease (CKD) [1]. It is associated with increased morbidity and mortality and might be related to an accelerated rate of CKD progression [1, 2]. The etiology of anemia in CKD is multifactorial but mainly occurs due to inadequate production of erythropoietin (EPO) [3, 4]. EPO is a glycoprotein composed of 166 aa, and its production occurs mainly in the kidneys. EPO acts as a peptide hormone on its specific receptor (EPOR), distributed in the most diverse tissues [4, 5]. However, EPO’s primary function is to act as a growth factor in erythropoiesis since it is essential for producing erythrocytes, thus maintaining tissue oxygenation at optimal levels [5, 6]. But some factors contribute to CKD-related anemia and decreased responsiveness to EPO, such as iron deficiency, inflammation, solutes, and uremic toxins [6–9]. Management of CKD-related anemia consists of erythropoiesis-stimulating agents (ESA) and iron replacement [10–12]. Even so, the blood transfusion required to treat anemia in patients with CKD continues to be widely used, especially in patients with inflammation status who progress to kidney failure with replacement therapy requirements [13, 14]. Moreover, red blood cell (RBC) transfusion presents risks and complications, such as infections and increased sensitization to HLA antigens for kidney transplantation [15, 16]. The soluble form of the Fas receptor (sFas) is produced as an alternative splicing product of CD95/ Fas mRNA or can be cleaved by metalloproteases that lack the transmembrane domain [17, 18]. Thus, sFas may deregulate CD95+-mediated apoptosis [9, 18–20]. Patients with CKD have a decreased kidney clearance of sFas [9, 21]. Previous research has shown a relationship between serum sFas levels with inflammation, cardiovascular disease, and anemia in patients with CKD [18, 22]. In addition, studies reported that serum sFas levels are associated with autoimmunity and hyporesponsiveness to EPO and are predictors of the need for ESA therapy in patients with CKD [9, 17]. Thus, firstly we decided to analyze and compare kidney function, anemia parameters, serum levels of inflammatory markers, EPO, and sFas between patients with non-dialysis dependent CKD (NDD-CKD) and healthy subjects. Afterward, we compared and evaluated the relationship between serum levels of sFas, EPO, and inflammatory markers with anemia over a long period in patients with NDD-CKD. So, the current study aims to analyze the association between serum sFas levels and anemia for an extended period in NDD-CKD patients. Materials and methods Patients and data collection We performed a retrospective study of NDD-CKD patients at the outpatient clinic of the Nephrology Service of the Federal University of São Paulo (UNIFESP) between late 2007 and 2019. In addition, we were able to evaluate data from our database that included patients with NDD-CKD from other publications. [9, 15, 19]. The current study was handled according to the guidelines of the Declaration of Helsinki of 1975, revised in 2013. The Institutional Committee on Human Research, Review and Ethics Board of the Federal University of São Paulo/UNIFESP, SP, Brazil approved the study (396/2004, 0108/2010, and 08636819.8.0000.5505/2019). No individual personal data was revealed or included in our study. All participating volunteers had access to the free and informed consent term. After reading, they signed it, authorizing and approving their participation. Volunteers who agreed to participate in the research could request their withdrawal from the study at any time without interference or discrimination in the treatment they were undergoing. Informed consent included using clinical data and results from anonymously extracted and personally de-identified sera. The researchers stored the patients’ data, and it is under total ethical secrecy. First, all the clinical data of the patients were obtained through the chart medical records. Then, we analyzed the clinical data and serum levels of pro-inflammatory markers, EPO, and sFas, in patients with CKD undergoing conservative treatment. Our data bank contains all the enrolled CKD patients with serum measurements of EPO, sFas, osteo-metabolic and inflammatory markers collected between December 2007 to July 2008. Next, the data from patients with CKD were compared with 20 healthy volunteer individuals. All healthy volunteers had no CKD, diabetes, or hypertension. Thus, the healthy subjects had an eGFR above 60 ml/min/1.73 m2 and no marker of kidney damage, such as proteinuria. Therefore, we formed the NDD-CKD and non-CKD groups and evaluated and compared some variables at baseline. So, we performed correlations of the variables in the study of NDD-CKD patients. After, we created two new other subgroups and realized comparisons of parameters at baseline between CKD patients with and without long-term anemia. The analysis of long-term anemia occurred by Hb concentration at the end of follow-up up to 12 years, at the last Hb assessment before initiating kidney replacement therapy, or in evaluating Hb concentration before death among all patients with NDD-CKD. Afterward, we performed multivariate analyzes between NDD-CKD patients using long-term anemia as a dependent variable and variables at baseline as predictor variables. For all analyses, 126 patients with NDD-CKD filled out the following inclusion criteria: age >18 years and CKD diagnosis for at least three months with CKD stages according to the eGFR between stages 1 to 5, ranging from 11.2 to 91.1 ml/min/1.73. All CKD patients have had proteinuria for at least three months, and blood tests at baselines, such as complete blood count, iron status, kidney function, and serum levels of molecules of interest measured in the study. The exclusion criteria were a change of center and nephrological medical service, referral for kidney transplantation with a living or deceased donor within six months of enrolling in the outpatient clinic, iron depletion, presence of hematological diseases, active bleeding, abnormality in mean corpuscular volume and mean corpuscular hemoglobin, and need for ESA within 30 days after admission to the Nephrology outpatient clinic. In addition, we also excluded patients with a diagnosis of neoplasia, chronic viral diseases such as human immunodeficiency virus, hepatitis B and C infection, and those who started dialysis as a kidney replacement therapy or died within three months of enrollment in the NDD-CKD outpatient clinic. Thus, we excluded 68 patients from the study (Fig 1). 10.1371/journal.pone.0286854.g001 Fig 1 Workflow diagram of patient selection. NDD-CKD, non-dialytic chronic kidney disease; ESA, erythropoiesis-stimulating agent; KRT, kidney replacement therapy. We collected clinical and demographic data at baseline from patient charts. They included age, sex, active smoking, CKD etiology, body mass index (BMI), complete blood count (hemoglobin concentration, hematocrit, hematological indices, leukocytes, and platelets), iron status, serum albumin, and medications in use, such as a renin-angiotensin system blocker, iron replacement, and use of ESAs. In addition, serum levels of pro-inflammatory markers(C-reactive protein [CRP], interleukin-6 [IL-6], and interferon-gamma [IFN-γ]), EPO, intact parathyroid hormone (iPTH), and sFas, were analyzed from our database of the same patients and with extracted blood sample in the exact period that the clinical tests were analyzed. We also computed the need for ESA, need for red blood cell transfusion, need for dialysis, and mortality as outcomes for up to 12 years of follow-up since admission to the Nephrology outpatient clinic. So the last follow-up and anemia data analysis were for up to 12 years. Or we also got data, such as Hb concentration, before initiating kidney replacement therapy or at the previous assessment before death among all patients with NDD-CKD. We used the sFas/eGFR ratio in correlations and comparisons because that is the molecule evaluated as a uremic retention solute related to clinical outcome. Anemia was defined as Hb<13.0 g/dl for men and postmenopausal women or Hb<12.0 g/dl for premenopausal women [1, 2, 9, 23]. ESA therapy started when the Hb level decreased to <10.0 g/dl or anemia-induced symptoms were present [9, 23]. The patient’s nephrologist determined all drug therapy. The indication of RBC transfusion was by the patient’s nephrologists, which we recovered from the patient’s medical chart history in whom ESA therapy was ineffective (e.g., erythropoietin resistance or patients with CKD and coronary heart disease with symptoms of anemia such as fatigue, reduced appetite, tiredness, and cognitive impairment) [11, 12, 23]. We calculated the estimated glomerular filtration rate (eGFR) using the CKD Epidemiology Collaboration formula. Thus, we followed the KDIGO criteria to define CKD when eGFR <60 ml/min/1.73m2 or by the presence of proteinuria for at least three consecutive months [24, 25]. Proteinuria was observed in a urine test by a dipstick and confirmed in a urine sample isolated by the colorimetric method (Analisa®, Belo Horizonte, Brazil). We considered proteinuria values greater than 10mg/dl by dipstick urine analysis (Cobas® 6500, Roche Diagnostics GmbH, Germany). Therefore, proteinuria with a value greater than 0.1g/l or when the albumin-to-creatinine ≥30mg/g over three months determined kidney damage [26]. We also used EPO/Hb ratio [18, 27] as an index of response to EPO to perform comparisons at baseline. Finally, we also did divide all NDD-CKD patients with higher and lower levels of sFas by the median of serum sFas levels. Thus, we analyzed two other new subgroups of serum sFas levels, higher and lower, to assess and compare the frequency of outcomes (need for ESA, blood transfusion requirement, progression from CKD to dialysis as kidney replacement therapy, and mortality). Serum levels The serum levels of sFas (BD Pharmingen™), EPO (Quantikine Human Erythropoietin Immunoassay R&D systems®, Minneapolis, MN, USA), interleukin-6 (BD OptEIA™ Human IL-6), Interferon-γ (BD OptEIA™ Human IFN-γ; BD Biosciences-Pharmingen, San Diego, CA USA), were measured using enzyme-linked immunosorbent assay, by the manufacturer’s instructions. In addition, we analyzed the intact parathyroid hormone (iPTH) and ferritin levels by chemiluminescent microparticle immunoassay with an automatized method (Abbott Laboratories™, IL, USA). Statistical analysis We performed the statistical analyses and graphs in Statistical Package for the Social Sciences (SPSS) version 22 (IBM, Armonk, New York, USA), Excel TM 16.0 (Microsoft, Redmond, Washington, USA), and GraphPad Prism (version 8.0; La Jolla, CA, USA). Numerical data are presented as the mean and standard error to assess the reliability of the norm. In addition, we reported the categorical variables as frequencies and percentages. In a comparative analysis, we performed the X2 test for frequencies of qualitative variables. The Kolmogorov-Smirnov test was performed to evaluate the normal distribution of continuous data. We carried out serum sFas levels divided by 1000 for statistical analysis. We completed the logarithmic transformation for the data that did not have a normal distribution. Student’s t-test was used to compare two groups for variables with normal distribution. Pearson’s correlation was performed to evaluate the association between two continuous variables. We carried out the backward stepwise binary logistic regression for admission data using end anemia as a variable response. Predictors variables were included in the multivariate model when they reached p<0.09 in the univariate analysis. Regression data were expressed as odds ratios (OR) and 95% confidence intervals (95% CI). It was considered significant at the statistical level of p<0.05. Ethical issues There is no individual personal data revealed or included in the current study. Our study was handled according to the guidelines of the Declaration of Helsinki of 1975, revised in 2013. The Institutional Committee on Human Research, Review and Ethics Board of the Federal University of São Paulo/UNIFESP, SP, Brazil approved the study (396/2004, 0108/2010, and 08636819.8.0000.5505/2019). All participating volunteers had access to the written free and informed consent terms. After reading, they signed it, authorizing and approving their participation. Volunteers who agreed to participate in the research could request their withdrawal from the study at any time without interference or discrimination in the treatment they were undergoing. Informed consent included using clinical data and results from anonymously extracted and personally de-identified sera. The researchers stored the patients’ data, and it is under total ethical secrecy. Our study did not interfere with the medical evaluation, request for laboratory tests, or patient management. The patient’s nephrologist ordered tests such as complete blood count, kidney function, and electrolytes when appropriate. In addition, the patient’s nephrologist indicated medications, including renin-angiotensin system blockers, ESA, iron and vitamin replacement, and RBCt when necessary. Results The leading causes of CKD were diabetes mellitus and hypertension. In addition, we observed that the NDD-CKD group was older and had higher BMI. Furthermore, the NDD-CKD group showed more elevated serum ferritin, urea, creatinine levels, serum levels of iPTH, sFas, C-reactive protein, IL-6, IFN-γ, sFas/eGFR, EPO/Hb ratio and lower eGFR, Hb, hematocrit (Ht) concentration, platelets, and serum albumin than healthy individuals (Table 1). 10.1371/journal.pone.0286854.t001 Table 1 Comparison of demographic data and clinical parameters at baseline between healthy volunteers and patients with non-dialysis chronic kidney disease. non-CKD group (n = 20) NDD-CKD group (n = 58) p Age (Years) 46.7±3.1 54.6±1.7 0.03 Gender (n, %)  Male 10 (50%) 35 (60.3%) 0.42  Female 10 (50%) 23 (39.7%) BMI (kg/m 2 ) 24.7±0.67 27.6±0.82 0.06 CKD etiology (n, %) -  DM - 25 (43.2%)  Hypertension - 17 (29.3%)  CGN - 6 (10.3%)  Other - 10 (17.2%) s-Cr (mg/dl) 1.02±0.03 2.25±0.12 <0.001 eGFR (ml/min/1.73m 2 ) 89.7±3.32 35.7±2.5 <0.001 s-Urea (mg/dl) 30.3±1.79 74.5±3.62 <0.001 Hb (g/dl) 14.4±0.25 12.8±0.27 0.003 Ht (%) 42.5±0.58 37.9±0.89 0.005 MCV (fL) 91.6±0.57 90.8±0.28 0.07 MCH (pg) 31.8±0.23 31.6±0.14 0.61 Leukocyte (cell/μl) 7415±344 7656±283 0.59 Platelet (x10 3 cell/μl) 303±9.7 219±6.9 <0.001 s-Albumin (g/dl) 4.6±0.14 4.07±0.06 <0.001 CRP (mg/dl) * 0.24±0.07 0.51±0.06 0.04 IL-6 (pg/ml) * 3.49±1.29 6.64±0.84 <0.001 IFN-γ (pg/ml) * 2.31±0.76 5.70±0.67 <0.001 sFas (pg/ml) 1136±97 2894±172 <0.001 sFas/eGFR (pg.ml-1/ml.min-1/1,73m2) * 13.2±1.37 119.9±13.6 <0.001 Serum EPO (mIU/ml) * 6.75±0.81 10.9±1.42 0.09 EPO/Hb (mIU/ml/mg.dl-1) * 4.90±0.58 8.76±1.16 0.003 iPTH (pg/ml) 40.0±2.09 187.4±20.2 <0.001 CKD, chronic kidney disease; BMI, body mass index; DM, diabetes mellitus; CGN, chronic glomerulonephritis; s-Cr, serum creatinine; eGFR, estimated glomerular filtration rate; s-Urea, serum urea; Hb, hemoglobin concentration; Ht, hematocrit concentration; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; s-Albumin, serum albumin; CRP,C-reactive protein; IL-6, interleukin-6; IFN-γ, interferon-gamma; sFas, soluble Fas; iPTH, intact parathyroid hormone; EPO, erythropoietin; *, after logarithmic transformation for statistical analysis. We performed correlations of the main variables in the 58 patients with NDD-CKD at baseline. There was a positive correlation between sFas/eGFR and EPO/Hb ratio (Fig 2), sFas levels and EPO/Hb ratio (r = 0.41, p = 0.001), sFas and iPTH levels (r = 0.35, p = 0.04), eGFR and platelets (r = 0.31, p = 0.02), CRP and IL-6 (r = 0.28, p = 0.04), and between sFas and IL-6 (r = 0.26, p = 0.04). We also found negative correlations between eGFR and sFas (r = -0.67, p<0.001), eGFR and IFN-γ (r = -0.42, p = 0.001), sFas and Hb (r = -0.40, p = 0.002), platelets and IL-6 (r = -0.39, p = 0.002), IFN-γ and platelets (r = -0.27, p = 0.04), and between eGFR and IL-6 (r = -0.23, p = 0.03). 10.1371/journal.pone.0286854.g002 Fig 2 Correlation between ratios of filtration of soluble Fas and resistance to erythropoietin at baseline (n = 58). sFas, serum soluble Fas; eGFR, estimated glomerular filtration rate; EPO, serum erythropoietin; Hb, hemoglobin concentration. Thus, we followed up on the 58 patients with NDD-CKD for 11.3 ±0.7 years. We observed 17 NDD-CKD patients who did not evolve with long-term anemia. Therefore, the long-term hemoglobin concentration was evaluated after 12 years of follow-up, before renal replacement therapy, or even before death. Moreover, 17 patients who were followed up for 12 years did not have long-term anemia but had higher eGFR at baseline. Meanwhile, 41 patients with long-term anemia had lower eGFR at baseline (Table 2), followed up to analyze Hb concentration and outcomes for 10.6±0.4 years. 10.1371/journal.pone.0286854.t002 Table 2 Comparison of factors at baseline between chronic kidney disease patients who had anemia and those who did not have anemia at the end of follow-up. Long-term Non-anemic (n = 17) Long-term Anemic (n = 41) p Age (Years) 44.5±3.4 58.8±1.7 0.001 Gender (n, %) 0.11  Male 13 (76.5) 22 (53.6)  Female 4 (23.5) 19 (46.4) BMI (kg/m 2 ) 26.3±0.88 28.2±1.10 0.19 DM (n, %) 2 (11.8) 23 (56.1) 0.002 Hypertension (n, %) 10 (58.8) 7 (17.1) 0.001 s-Cr (mg/dl) 1.7±0.13 2.49±0.14 <0.001 eGFR (ml/min/1.73m 2 ) 54.9±5.26 27.7±.1.72 <0.001 s-Urea (mg/dl) 51.9±5.22 83.8±3.80 <0.001 Hb (g/dl) 14.9±0.30 12.1.±0.28 0.004 Ht (%) 42.6±1.9 36.1±1.89 0.004 MCV (fL) 90.6±0.50 90.7±0.34 0.96 MCH (pg) 31.5±0.28 31.8±0.16 0.47 Transferrin saturation (%) 27.4±2.5 27.1±1.7 0.91 Ferritin (μg/L) 95.7±18.9 89.2±12.3 0.77 s-Albumin (g/dl) 4.05±0.12 4.08±0.07 0.87 CRP (mg/dl) * 0.49±0.12 0.51±0.07 0.69 IL-6 (pg/ml) * 4.02±0.69 7.72±1.10 0.02 IFN-γ (pg/ml) * 6.73±2.12 5.28±0.37 0.31 sFas (pg/ml) 1820±240 3339±181 0.001 sFas/eGFR(pg.ml -1 /ml.min -1 /1,73m 2 ) * 45.2±9.95 150.9±16.6 <0.001 Serum EPO (mIU/ml) * 7.62±1.02 12.3±1.94 0.12 EPO/Hb (mIU/ml/mg.dl -1 ) * 5.12±0.69 10.3±1.56 0.04 iPTH (pg/ml) 156±25.3 195±26.7 0.38 Use of RAS blocker 12 (70.6%) 35 (85.3) 0.19 Active smoking (n, %) 6 (35.3) 18 (43.9) 0.54 BMI, body mass index; DM, diabetes mellitus; s-Cr, serum creatinine; eGFR, estimated glomerular filtration rate; s-Urea, serum urea; Hb, hemoglobin concentration; Ht, hematocrit concentration; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; s-Albumin, serum albumin; CRP,C-reactive protein; IL-6, interleukin-6; IFN-γ, interferon-gamma; sFas, soluble Fas; iPTH, intact parathyroid hormone; EPO, erythropoietin; RAS blocker, renin-angiotensin system blocker; *, after logarithmic transformation for statistical analysis. So, we also observed in Table 2 lower Hb and Ht concentrations at baseline in patients with NDD-CKD in the long-term anemia group than in patients who evolved without anemia after an extensive time. On the other hand, the long-term anemia group had higher creatinine, urea, serum IL-6, sFas levels (Fig 3), EPO/Hb, and sFas/eGFR ratio at baseline than the patients without long-term non-anemia. 10.1371/journal.pone.0286854.g003 Fig 3 Comparison of soluble-Fas at baseline between anemic patients (n = 41) and non-anemic patients (n = 17) after follow-up. sFas, soluble Fas; CKD, chronic kidney disease. Table 3 shows that diabetes mellitus, higher age, and serum levels of sFas at baseline were independently associated with anemia after an extensive period in patients with NDD-CKD. 10.1371/journal.pone.0286854.t003 Table 3 Binary logistic regression of anemia at the end of the follow-up as the response variable and its predictors at baseline. Long-term Anemia vs. Non-anemia 95% CI for OR OR Lower Upper P value DM 13.038 1.037 163.879 0.04 sFas (pg/ml) 4.322 1.464 12.753 0.008 Age (years) 1.094 1.012 1.183 0.02 s-Cr (mg/dl) 2.045 0.524 7.984 0.30 IL-6 (pg/ml) * 1.118 0.905 1.381 0.31 EPO/Hb (mIU/ml/mg.dl -1 ) * 1093 0.815 1.465 0.55 Hypertension 0.785 0.101 6.111 0.82 R2 = 0.883; Global model (p = 0.002); OR, odds ratio; 95% CI, 95% confidence interval; DM, diabetes mellitus; sFas, soluble Fas; s-Cr, serum creatinine; EPO, erythropoietin; Hb, hemoglobin; *, after logarithmic transformation for statistical analysis. Furthermore, we observed that the last eGFR (15.5±2.4, 34.6±8.4 ml/min/1.73; p = 0.002) and hemoglobin concentration (10.2±0.3, 14.2±0.6 g/dl; p<0.001) analyzed at the end of follow-up were lower in patients who evolved with anemia in the same period of analysis, that is, long term anemia. We observed that the median of sFas serum levels was 2294 at baseline. Finally, another division of groups to perform comparisons occurred as follows, higher sFas subgroup when the sFas levels of patients were higher than 2294 pg/ml, and lower sFas for patients with lower serum levels or equal 2294 pg/ml. Eighteen (46.2%) of the thirty-nine patients with NDD-CKD and high serum sFas levels (>2294 pg/ml) required ESA to treat kidney anemia. The CKD patients started ESA therapy with recombinant human erythropoietin 5±2.5 months after admission to the Nephrology outpatient clinic at UNIFESP. Seven (17.9%) of the 39 NDD-CKD patients with higher sFas levels needed RBC transfusion to treat anemia over the 12 years of follow-up. Blood transfusions occurred after 73±12 months of admission to the CKD clinic and enrollment in the study. They received 1.7±0.3 units of red blood cells. No patient with NDD-CKD and low sFas levels (<2294 pg/ml) developed anemia requiring ESA therapy or RBC transfusion. Moreover, eleven patients (28.2%) of 39 with higher sFas levels evolved with the need for hemodialysis within 26.6±7.2 months. No patient with low serum sFas levels (<2294 pg/ml) at study enrollment became with the need for hemodialysis over 12 years of follow-up. Finally, we observed mortality in four NDD-CKD patients with higher levels of sFas (10.3%) in 82.5+31.6 months over 12 years. At the same follow-up time, one of nineteen (5.3%, p<0.001) patients with lower serum sFas levels showed the same evolution after 89 months. Discussion The relationship of sFas with kidney anemia and outcomes has become evident and scientifically robust in current research. Interestingly, we found higher serum levels of sFas in CKD than in healthy individuals. There was also a positive correlation of sFas with both resistance index to the action of EPO (measured by EPO/Hb) and inflammation (measured by IL-6). Even so, sFas also had a negative correlation with both kidney function (eGFR) and Hb concentration, suggesting an association of serum sFas levels with decreasing kidney function and kidney anemia. We found an independent association in the multivariate analysis of serum sFas levels with long-term kidney anemia. In addition, there was a greater frequency of need for ESA therapy and blood transfusion to treat kidney anemia in the long-term follow-up in patients with more elevated baseline serum sFas levels. More frequent incidences of dialysis and mortality cases also occurred in NDD-CKD patients with higher baseline serum levels. These all were the most critical findings in the current study. Anemia is frequent in patients with NDD-CKD. For example, Minutolo et al. reported that the prevalence of anemia in NDD-CKD patients was 39.6% in a study from Italy. Furthermore, the incidence and prevalence of anemia in these patients increased in parallel with the CKD stage [27]. In addition, Gill et al. observed in another study with NDD-CKD that the RBC transfusion rate to treat kidney anemia was 2.64/100 person-years. Still, the RBC transfusion rates were higher among those who progressed to kidney failure requiring kidney replacement therapy, with 28.0/100 person-years [28]. Fox et al. previously reported that approximately 20% of patients with NDD-CKD received RBC transfusion to treat kidney anemia [29]. ESA and blood transfusion are typical for treating anemia in patients with CKD and occur with a specific frequency for patients who have CKD progression and are starting kidney replacement therapy or patients who are resistant to the action of ESA, respectively [9, 27–32]. However, red blood cell transfusion increases sensitization to HLA antigens. Therefore, it makes subsequent kidney transplantation more problematic, in addition to the risk of infectious diseases, such as viral hepatitis B and C, as well as HIV, among others, which can increase the severity during immunosuppression [32, 33]. However, we could look further to find molecules associated with kidney anemia, studying serum levels of uremic retention solute related to patients with NDD-CKD. Thus, we could later research new markers of kidney anemia. Therefore, we undertook the present study to determine the association of serum sFas levels with kidney anemia, ESA requirement, and the need for red cell transfusion in patients with NDD-CKD to obtain more information on the long-term relationship between a uremic retention solute, sFas, and anemia. Moreover, we also investigated the relationship and frequency of sFas with mortality in patients with NDD-CKD. Thus, the initial phase of the current study compared healthy subjects with patients with CKD-NDD through demographic data, kidney function using estimated GFR [25, 26], complete blood count, and some molecules, such as levels of inflammatory markers, iPTH, and sFas. We found that patients with NDD-CKD had anemia, higher levels of sFas, inflammatory markers, and elevated iPTH levels. However, our data still showed low levels of platelets and serum albumin. In addition, we observed a higher rate of inadequate response to EPO through an elevated EPO/Hb ratio in patients with CKD [34]. Our study reproduced previous findings related to the increase in sFas [9, 18], as well as the lower EPO response [34]; the findings of this work agree with recent studies, which show the increase in inflammatory markers [35] and iPTH [36], but they also offer the low EPO responsiveness [34, 37]. Forty-one patients (70.7%) with NDD-CKD were diagnosed with anemia after an extended period of the current study. Thus, we analyzed and compared clinical factors, serum inflammatory markers, EPO, and sFas levels from the baseline levels between patients with and without anemia within up to 12 years of follow-up. We found that the sFas/eGFR and EPO/Hb ratios at baseline were higher in patients with long-term anemia, suggesting that sFas is associated with EPO hyporesponsiveness. Moreover, serum levels of sFas were higher when there was a lower eGFR in an inverse correlation. Many patients with kidney anemia often have chronic inflammation [38, 39]. Therefore, we found higher serum levels of sFas and pro-inflammatory markers (IL-6, IFN-γ, and CRP) in patients with NDD-CKD than in healthy subjects in our study. In addition, we observed higher baseline serum IL-6 levels in patients who evolved with long-term anemia. Our findings are in line with recent studies in which patients with CKD have high values of IL-6 [40], IFN-γ [41], and CRP [42]. Inflammatory cytokines directly affect cell differentiation in the erythroid pathway, mediating the induction of cell death, reducing intestinal iron absorption, and increasing iron sequestration by cells of the reticuloendothelial system [38, 39]. Even though, in this study, we did not observe differences in iron status in patients with NDD-CKD who did or did not have long-term anemia. Some uremic toxins may contribute to anemia in CKD; for example, indoxyl sulfate is a protein-bound uremic toxin that acts in anemia due to impaired EPO synthesis by the kidneys due to a suppression of the EPO gene transcription in a factor hypoxia-inducted factor and promotes suppression of the EPO receptor (EPOR)-AKT pathway [43, 44]. Thus, we sought to study the relationship between sFas and long-term kidney anemia. We also examined the relation of serum sFas with the treatment of kidney anemia, such as the need for ESA therapy and RBC transfusion. Because sFas is a molecule that can be considered a uremic retention solute. The sFas is a molecule of approximately 42.3 kDa and arises from alternative splicing or shearing of the CD95+ receptor. Patients with CKD have elevated serum sFas levels related to inflammatory markers, dysregulation of apoptosis, and outcomes [9, 18, 45, 46]. Furthermore, our group has previously reported lower sFas renal clearance in patients with increased serum levels sFas, which was associated with anemia, hyporesponsiveness to EPO, and increased need for ESA in patients with CKD during six years of follow-up, in addition to inhibiting erythroid cell growth in vitro [9, 18, 21]. The current study found an association between the serum sFas levels at baseline and kidney anemia observed over a long follow-up period. We also found a higher frequency of need for ESA therapy and a need for RBC transfusion over 12 years in patients with NDD-CKD. Furthermore, we report that serum sFas level was independently associated with kidney anemia. We showed that for each increase of 1,000 pg/ml in serum sFas levels, there is a 4.3 times greater chance of the individual developing anemia up to 12 years of follow-up. Beyond that, during up to 12 years of follow-up, we found a 13 times more chance of developing anemia when the NDD-CKD patient had diabetes mellitus. Other researchers previously reported that hyperglycemia determines hypoxic stress in the kidney interstitium, impairing erythropoietin production, and anemia in diabetes aggravates diabetic kidney disease and cardiovascular disease [47]. Our findings showed an independent association between age and kidney anemia. Yang et al. observed that kidney anemia is frequent and an independent risk factor for decreased kidney function among middle-aged and older people [48]. The current study still had a higher incidence of dialysis and mortality in NDD-CKD patients with higher serum sFas. Although enthusiastic, the present study has some limitations, such as i) it is a retrospective study, ii) the researchers did not carry out any intervention in the group of patients; iii) the small sample size of patients and healthy volunteers; and finally, iv) a possible selection bias, as we focused on patients with NDD-CKD and serum levels of inflammatory markers and sFas that are associated with anemia and hyporesponsiveness to EPO, with most of the patients from our database already reported [9, 18, 21], and therefore we see that more studies will be necessary to reinforce our findings. On the other hand, our findings have important implications for understanding the clinical expression when categorizing sFas as a possible marker or even if it is a possible uremic retention solute and, thus, might contribute to the development of new studies that focus on pathophysiological processes, and possibly, the treatment of anemia in patients with CKD, as with newer ESA drugs [49–51]. Conclusion In conclusion, this study has documented that patients with NDD-CKD have higher serum levels of sFas, IL-6, IFN-γ, C-reactive protein, iPTH, and EPO/Hb ratio than healthy subjects. In addition, the serum sFas, IL-6 levels, and EPO/Hb ratio at baseline were higher in NDD-CKD patients that evolved with long-term kidney anemia. Moreover, age, diabetes mellitus, and serum sFas levels at baseline were independently associated with anemia over a prolonged follow-up period in patients with CKD. Even so, blood transfusion and ESA requirements to treat anemia during up to 12 years of follow-up were higher in patients with elevated serum sFas levels. However, the present study may point to new paths or tests of another uremic retention solute, sFas, with toxic clinical effects in CKD. Consequently, more clinical and pathophysiological studies are necessary for a possible marker of therapeutic intervention for kidney anemia or a new tool therapy to treat anemia associated with CKD. We thank all patients, healthy volunteers, professionals, and technicians from the Federal University of São Paulo involved in this work for supporting the study. We thank Professor Nestor Schor (in memoriam) for all his assistance and consideration. 10.1371/journal.pone.0286854.r001 Decision Letter 0 Kannan Lakshmi Academic Editor © 2023 Lakshmi Kannan 2023 Lakshmi Kannan https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Submission Version0 3 Mar 2023 PONE-D-23-00605A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney diseasePLOS ONE Dear Dr. Andrade, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Comments to the authors:1. Respond point-by-point to the reviewers' comments. 2. Check the manuscript for grammatical and syntax errors. 3. Discussion section needs to be rewritten.  Please submit your revised manuscript by Apr 17 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Lakshmi Kannan Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information. If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. 3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access. We will update your Data Availability statement to reflect the information you provide in your cover letter. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: These are my comments to the author: In Material, Methods section: - It is a retrospective study for non-dialysis CKD patients presented to outpatient clinics, you should give some details about stages of CKD you are followed - You followed only 97 patients? - You should specify the date of sample collections and then the follow up period - You have used healthy control group; you should give some details about how you chose them - During follow up period which is 12 years, what about outcomes, how many patients, is any patient started dialysis, is there any patients died, any patients transplanted, also you mentioned the exclusion criteria, is it on initial screening or during follow up period? - Retrospective study means you depend on patients file review, do you do routine laboratory tests including pro-inflammatory cytokines and sFAS??? Result section: - In table 1 the number on control group is 20, however, in the flow chart figure, the number is 21m which one is correct? - The mean eGFR for NDD-CKD was 35.7ml/m±2.5, however the eGFR after 12 years follow up for non-anemic NDD-CKD patients in table 2 was 54.9±5.26, is it worth for CKD patients over the long period of follow up?? It should be lower than at the initial presentation? - It is better to compare between groups at initial presentation and after follow up period - There are few language errors like in row 8 after table 3 (seven (17.9%) out of 39, the correct out of - Discussion part: - The discussion section looks more as an introduction part with no more details regarding comparing your study with other previous studies - There are some few language errors in some words for correction please Reviewer #2: Comments 1- There are few grammar mistakes, confused sentences, and typos throughout the manuscript. It should be revised carefully. 2- The introduction should be one way or another to be extended to include dissertation about erythropoietin (EPO). 3- References should be updated in both the introduction and the discussion (lack of 2021 &2022 references). 4- Results are well organized, but correlations were not discussed in the discussion part of the manuscript. 5- The discussion is poor and lack explanations of many subtracted points, in addition it should be extended; more other previous studies in the same area of the present study should be used to show that the present results match or do not with that of other previous studies. 6- The conclusion was limited only to diabetes mellitus, age, and higher serum sFas levels although the study includes several other variables such as Hb, serum albumin IL-6, IFN-γ, Serum EPO and iPTH which were not discussed well. 7- There are some weak points in the present study: First, the sample sizes of the patients, and the healthy volunteers who participated in the study were small as proven in the article by the authors and this is againt editorial policies and submission guidelines of PLOS ONE. Also, the researchers did not carry out any intervention in the group of patients and they focused on patients with NDDCKD and serum levels of inflammatory markers (which were not referred to in the discussion) and sFas that are associated with anemia and hyporesponsiveness to EPO, with most of the patients already reported. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. Attachment Submitted filename: Comments on PLOS ONE article.docx Click here for additional data file. 10.1371/journal.pone.0286854.r002 Author response to Decision Letter 0 Submission Version1 1 May 2023 To the Academic Editor: 1. Respond point-by-point to the reviewers' comments. #1Comments, we appreciate the comments of all reviewers, and we have modified all suggested points in detail. 2. Check the manuscript for grammatical and syntax errors. #2Comments, we greatly appreciate this comment and reinforce the correction of grammar and syntax errors. 3. Discussion section needs to be rewritten. #3Comments, we’d like to thank you for the comment. We emphasize that several parts of the discussion were modified, aiming to adapt the language, clarify information and further enrich the content. Corrections related to journal requirements All the notes made by the journal were made by the authors, which included: the revision of the formatting, notes added to the topic ‘’ethical issues’’, and the clarification related to the Data Availability statement. _________________________________________________________________ Comments to the authors: Reviewer #1: In Material, Methods section: 1- It is a retrospective study for non-dialysis CKD patients presented to outpatient clinics, you should give some details about stages of CKD you are followed 1#Comments, Correspondent author: We thank you a lot for this important observation. Yes, We followed up with 58 patients diagnosed with CKD undergoing conservative treatment between stages 1 to 5 according to the eGFR, which ranged from 11.2 to 91.1 ml/min/1.73, and proteinuria after exclusion criteria. Here eight individuals in stage 1 or 2 who had been healthy volunteers with eGFR >60 but had a marker of kidney damage - proteinuria in late 2007/early 2008 in urine analysis in samples collected and analyzed with an interval of more than three months. So, they are currently our CKD outpatients since the diagnosis. As suggested, we wrote the patients' stages and eGFR in the Materials and Methods section. 2- You followed only 97 patients? 2#Comments, Correspondent author: Thank you again for this comment. In fact, in our database, there were 126 outpatients admitted between December 2007 and July 2008 with CKD under conservative treatment, presenting an evaluation of blood count, iron status, kidney function, and urine I. In parallel, they were enrolled for research in our database, with measurement of serum levels of sFas, EPO, osteo-metabolic, and inflammatory markers. We had not reported these patients before because 29 patients changed centers or were followed up for kidney transplants within six months of registration in our database. As amended, described in the main text and Figure 1 after we've looked it over carefully. Thus, we could follow up with 58 patients with CKD after exclusion criteria over 12 years. 3- You should specify the date of sample collections and then the follow up period. 3#Comments, Correspondent author: We thank you for this information, and we have edited all method sections to describe better the date of sample collections and the follow-up period. We also computed the need for ESA, need for red blood cell transfusion, need for dialysis, and mortality as outcomes over 12 years of follow-up since admission to the Nephrology outpatient clinic. So the last follow-up and anemia data analysis were for up to 12 years. Thus, we also got data before initiating kidney replacement therapy or at the previous assessment before death among all patients with NDD-CKD. 4- You have used healthy control group; you should give some details about how you chose them. 4#Comments, Correspondent author: Thank you for this encouraging comment. We have included more details about the healthy volunteers in the second paragraph in Patients and Data collection. 5- During follow up period which is 12 years, what about outcomes, how many patients, is any patient started dialysis, is there any patients died, any patients transplanted, also you mentioned the exclusion criteria, is it on initial screening or during follow up period? 5#Comments, Correspondent author: Thank you for this critical observation. We have reported the outcomes in Methods and Results. So, we have computed the need for ESA, need for red blood cell transfusion, need for dialysis, and mortality as outcomes for up to 12 years of follow-up since admission to the Nephrology outpatient clinic. During the 12 years of follow-up, 11 patients required a dialysis program. Unfortunately, there were five non-survivor patients over 12 years of follow-up. 6- Retrospective study means you depend on patients file review, do you do routine laboratory tests including pro-inflammatory cytokines and sFAS??? 6#Comments, Correspondent author: Thank you for this relevant point. In the current study, we have included patients with iron status, complete blood count, kidney function, and urine analysis and collected that patient data from charts. In addition, we have a database for research with serum analysis of sFas, inflammatory markers, and bone profiles parallel to the charts' clinical data. Prof. Miguel Angelo has been studying serum levels of sFas, and inflammatory markers related to anemia in CKD since his Master's degree. Thus, he stores the database safely and ethically. Therefore, after 12 years of follow-up and observing outcomes, we decided to publish these data with approval by the ethics committee of UNIFESP. Result section: 7- In table 1 the number on control group is 20, however, in the flow chart figure, the number is 21m which one is correct? 7#Comments, Correspondent author: Thank you for this critical observation. We have made a mistake in typing. The correct number is 20 healthy individuals. We corrected it in the figure and the main text. 8- The mean eGFR for NDD-CKD was 35.7ml/m±2.5, however the eGFR after 12 years follow up for non-anemic NDD-CKD patients in table 2 was 54.9±5.26, is it worth for CKD patients over the long period of follow up?? It should be lower than at the initial presentation? 8#Comments, Correspondent author: Thank you for this critical observation. We appreciate your intelligent and solid question. We redid all the statistical analysis and looked over the typing again. In fact, we retitled Table 2 for clarity. Thus, in this table and the results in the main body of the text, we analyzed two more subgroups of 58 patients with CKD for the long-term anemia outcome. Thus, we were able to compare patients with CKD and anemia in the long term and patients with CKD without anemia for a long time. However, baseline eGFR, as expected, was higher in the group without long-term anemia (54.9±5.26 ml/min/1,73).Consequently, we used baseline variables in these comparisons and then performed binary logistic regression with long-term anemia as the dependent variable. However, these analyses supported our hypothesis, as these two subgroups did not have statistically significant serum EPO levels, although patients with long-standing anemia had higher EPO values. These same patients had higher levels of sFas, sFas/eGFR ratio, and EPO/Hb, indicating that the lower relative production is the main factor of anemia but that some uremic solutes retained in renal dysfunction contribute to anemia in these patients. 9- It is better to compare between groups at initial presentation and after follow up period 9#Comments Correspondent author: Again, thanks for your critical opinion. We believe there was a mistake from us, and for better understanding, we changed the title of Table 2 to “Comparison of factors at baseline between chronic kidney disease patients who had anemia and those who did not have anemia at the end of follow-up”. We compared the eGFR values at baseline of patients with CKD-NDD who did not have long-term anemia (54.9±5.26) with those who were long-time anemic (27.7±.72 ), both at the end of the follow-up. 10- There are few language errors like in row 8 after table 3 (seven (17.9%) out of 39, the correct out of 10#Comments, Correspondent author: Thanks a lot. As suggested, we have made changes for better understanding. Discussion part: 11- The discussion section looks more as an introduction part with no more details regarding comparing your study with other previous studies 11#Comments, Correspondent author: Again, thank you for your opinion. We sought to enrich the Discussion section by comparing our findings with recent archives in the literature. 12- There are some few language errors in some words for correction please 12#Comments, Correspondent author: Thank you. As suggested we try to fix language errors in the Discussion section Reviewer #2 1- There are few grammar mistakes, confused sentences, and typos throughout the manuscript. It should be revised carefully. 1.2#Comments, Correspondent author: Thank you for this comment. As suggested, we carefully proofread the text, removing confusing phrases. 2- The introduction should be one way or another to be extended to include dissertation about erythropoietin (EPO). 2.2#Comments Correspondent author: Again, thanks for your critical opinion. As suggested, we have included more concepts about erythropoietin (EPO) in the introduction. 3- References should be updated in both the introduction and the discussion (lack of 2021 &2022 references). 3.2#Comments, Correspondent author: Many thanks, for your opinion. As suggested, we have included new references in the Introduction and Discussion section after careful reading and review in line with our writing. 4- Results are well organized, but correlations were not discussed in the discussion part of the manuscript. 4.2#Comments, Correspondent author: Thank you again for this comment. As suggested, we reported the relationship of sFas (the focus of our study) with eGFR and some results of the correlation between sFas and both erythropoietin hyporesponsiveness (EPO/Hb ratio) and inflammation (IL-6) in the Discussion Sector. 5- The discussion is poor and lack explanations of many subtracted points, in addition it should be extended; more other previous studies in the same area of the present study should be used to show that the present results match or do not with that of other previous studies. 5.2#Comments, Correspondent author: Thank you for this critical observation. As suggested, the discussion has been expanded and matched with other research. 6- The conclusion was limited only to diabetes mellitus, age, and higher serum sFas levels although the study includes several other variables such as Hb, serum albumin IL-6, IFN-γ, Serum EPO and iPTH which were not discussed well. 6.2#Comments, Correspondent author: Again, thank you for this critical observation. As suggested, we discuss more Hb, IL-6 serum albumin, IFN-γ, serum EPO and iPTH in the Discussion Sector. Thus, as suggested, we have included a few more inflammatory markers in the Discussion and Conclusion. 7- There are some weak points in the present study: First, the sample sizes of the patients, and the healthy volunteers who participated in the study were small as proven in the article by the authors and this is againt editorial policies and submission guidelines of PLOS ONE. Also, the researchers did not carry out any intervention in the group of patients and they focused on patients with NDDCKD and serum levels of inflammatory markers (which were not referred to in the discussion) and sFas that are associated with anemia and hyporesponsiveness to EPO, with most of the patients already reported. 7.2#Comments, Correspondent author: We appreciate this feedback, critical observation, and opinion. Indeed, as we reported in the manuscript, our study had many limitations. Our sample size at enrollment was larger by our database, which is stored safely and ethically. However, there were many reasons for exclusion, such as the preferential request for a referral for a kidney transplant in the first six months of outpatient follow-up, even non-survival or need for dialysis, or use of ESA in the first three months of outpatient follow-up. In addition, there were severe comorbidities such as HIV, chronic hepatitis, neoplasms, or even hematological diseases that directly interfered with the anemia of these patients. Likewise, our control group was initially formed by 30 volunteers. All of them were employees from our University environment (not described in the manuscript). Of these, seven were excluded due to incomplete data. Unfortunately, two still died in the pandemic, and one asked to no longer participate in the study. Attachment Submitted filename: Response to Reviewers.doc Click here for additional data file. 10.1371/journal.pone.0286854.r003 Decision Letter 1 Kannan Lakshmi Academic Editor © 2023 Lakshmi Kannan 2023 Lakshmi Kannan https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Submission Version1 25 May 2023 A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease PONE-D-23-00605R1 Dear Dr. Andrade, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Lakshmi Kannan Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: 10.1371/journal.pone.0286854.r004 Acceptance letter Kannan Lakshmi Academic Editor © 2023 Lakshmi Kannan 2023 Lakshmi Kannan https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 22 Jun 2023 PONE-D-23-00605R1 A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease Dear Dr. Andrade: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Lakshmi Kannan Academic Editor PLOS ONE ==== Refs References 1 Singh AK , Cizman B , Carroll K , McMurray JJV , Perkovic V , Jha V , et al . Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022;182 (6 ):592–602. doi: 10.1001/jamainternmed.2022.0605 .35377393 2 Toft G , Heide-Jorgensen U , van Haalen H , James G , Hedman K , Birn H , et al . Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. J Nephrol. 2020;33 (1 ):147–56. doi: 10.1007/s40620-019-00652-9 .31587136 3 Xu Y , Evans M , Barany P , James G , Sjolander A , Carrero JJ . Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study. Clin Kidney J. 2021;14 (7 ):1780–8. doi: 10.1093/ckj/sfaa213 .34221385 4 Huang Q , Liao Z , Liu X , Xia Y , Wang J . Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis. Int Urol Nephrol. 2023;55 (2 ):325–34. doi: 10.1007/s11255-022-03316-z .35960479 5 Suresh S , Rajvanshi PK , Noguchi CT . The Many Facets of Erythropoietin Physiologic and Metabolic Response. Front Physiol. 2019;10 :1534. doi: 10.3389/fphys.2019.01534 .32038269 6 Tsiftsoglou AS . Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine. Cells. 2021;10 (8 ). doi: 10.3390/cells10082140 .34440909 7 Riccio E , Sabbatini M , Capuano I , Pellegrino AM , Petruzzelli LA , Pisani A . Oral Sucrosomial(R) iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. BMC Nephrol. 2020;21 (1 ):57. doi: 10.1186/s12882-020-01716-w .32087684 8 Olivari V , Di Modica SM , Lidonnici MR , Aghajan M , Cordero-Sanchez C , Tanzi E , et al . A single approach to targeting transferrin receptor 2 corrects iron and erythropoietic defects in murine models of anemia of inflammation and chronic kidney disease. Kidney Int. 2023. doi: 10.1016/j.kint.2023.03.012 .36990212 9 Chiloff DM , de Almeida DC , Dalboni MA , Canziani ME , George SK , Morsi AM , et al . Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease. Am J Physiol Renal Physiol. 2020;318 (4 ):F861–F9. doi: 10.1152/ajprenal.00433.2019 .32003597 10 Alexandre AF , Morga A , Thomas C , Krucien N , Tervonen T , Jiletcovici A , et al . Preferences for Anaemia Treatment Attributes among Patients with Non-Dialysis-Dependent Chronic Kidney Disease. Adv Ther. 2023;40 (2 ):641–57. doi: 10.1007/s12325-022-02367-z .36449257 11 Zaoui P , Courivaud C , Rostoker G , Choukroun G , Dubel L , Lorenzo M , et al . Management of anaemia in French dialysis patients: results from a large epidemiological retrospective study. Clin Kidney J. 2023;16 (3 ):501–11. doi: 10.1093/ckj/sfac245 .36865005 12 Roldao M , Escoli R , Goncalves H , Lobos AV . Efficiency of ferric carboxymaltose in non-dialysis CKD patients and its impact on kidney function: a prospective observational study. Int Urol Nephrol. 2023;55 (4 ):953–9. doi: 10.1007/s11255-022-03360-9 .36173535 13 Pergola PE , Pecoits-Filho R , Winkelmayer WC , Spinowitz B , Rochette S , Thompson-Leduc P , et al . Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review. Pharmacoecon Open. 2019;3 (4 ):463–78. doi: 10.1007/s41669-019-0132-5 .30968369 14 St Peter WL , Guo H , Kabadi S , Gilbertson DT , Peng Y , Pendergraft T , et al . Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrol. 2018;19 (1 ):67. doi: 10.1186/s12882-018-0861-1 .29544446 15 Laperche S , Maugard C , Lhomme S , Lecam S , Ricard C , Dupont I , et al . Seven years (2015–2021) of blood donor screening for HEV-RNA in France: lessons and perspectives. Blood Transfus. 2023;21 (2 ):110–8. doi: 10.2450/2022.0052-22 .35969132 16 Elkind J , Sobczyk J , Ostberg-Braun O , Silva Enciso J , Adler E , Morris GP . Factors influencing transfusion-associated HLA sensitization in patients bridged to heart transplantation using ventricular assist device. Clin Transplant. 2020;34 (1 ):e13772. doi: 10.1111/ctr.13772 .31845395 17 Seyrek K , Ivanisenko NV , Wohlfromm F , Espe J , Lavrik IN . Impact of human CD95 mutations on cell death and autoimmunity: a model. Trends Immunol. 2022;43 (1 ):22–40. doi: 10.1016/j.it.2021.11.006 .34872845 18 Goes MA , Dalboni MA , Manfredi SR , Cendoroglo MS , Batista MC , Canziani ME , et al . Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease. Clin Nephrol. 2010;73 (1 ):7–13. doi: 10.5414/cnp73007 .20040346 19 Carlile GW , Smith DH , Wiedmann M . A non-apoptotic role for Fas/FasL in erythropoiesis. FEBS Lett. 2009;583 (4 ):848–54. doi: 10.1016/j.febslet.2009.01.047 .19244619 20 Vilys L , Peciuliene I , Jakubauskiene E , Zinkeviciute R , Makino Y , Kanopka A . U2AF—Hypoxia-induced fas alternative splicing regulator. Exp Cell Res. 2021;399 (1 ):112444. doi: 10.1016/j.yexcr.2020.112444 .33347855 21 Dalboni MA , Cenedeze MA , Manfredi SR , Cruz Andreoli MC , Pavao Dos Santos O , et al . High serum levels of soluble Fas (sFas) in CKD patients: effects of renal clearance, reabsorption and synthesis. Int J Artif Organs. 2008;31 (5 ):405–10. doi: 10.1177/039139880803100505 .18609513 22 Claro LM , Moreno-Amaral AN , Gadotti AC , Dolenga CJ , Nakao LS , Azevedo MLV , et al . The Impact of Uremic Toxicity Induced Inflammatory Response on the Cardiovascular Burden in Chronic Kidney Disease. Toxins (Basel). 2018;10 (10 ). doi: 10.3390/toxins10100384 .30249039 23 Drueke TB , Parfrey PS . Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012;82 (9 ):952–60. doi: 10.1038/ki.2012.270 .22854645 24 Inker LA , Eneanya ND , Coresh J , Tighiouart H , Wang D , Sang Y , et al , Chronic Kidney Disease Epidemiology C. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385 (19 ):1737–49. doi: 10.1056/NEJMoa2102953 .34554658 25 de Boer IH , Caramori ML , Chan JCN , Heerspink HJL , Hurst C , Khunti K , et al . Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int. 2020;98 (4 ):839–48. doi: 10.1016/j.kint.2020.06.024 .32653403 26 Chen TK , Knicely DH , Grams ME . Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019;322 (13 ):1294–304. doi: 10.1001/jama.2019.14745 .31573641 27 Minutolo R , Grandaliano G , Di Rienzo P , Snijder R , Degli Esposti L , Perrone V , et al . Prevalence, incidence, and treatment of anaemia in patients with non-dialysis-dependent chronic kidney disease: findings from a retrospective real-world study in Italy. J Nephrol. 2023;36 (2 ):347–57. doi: 10.1007/s40620-022-01475-x .36370331 28 Gill KS , Muntner P , Lafayette RA , Petersen J , Fink JC , Gilbertson DT , et al . Red blood cell transfusion use in patients with chronic kidney disease. Nephrol Dial Transplant. 2013;28 (6 ):1504–15. doi: 10.1093/ndt/gfs580 .23389999 29 Fox KM , Yee J , Cong Z , Brooks JM , Petersen J , Lamerato L , et al . Transfusion burden in non-dialysis chronic kidney disease patients with persistent anemia treated in routine clinical practice: a retrospective observational study. BMC Nephrol. 2012;13 :5. doi: 10.1186/1471-2369-13-5 .22273400 30 Hanna RM , Streja E , Kalantar-Zadeh K . Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Adv Ther. 2021;38 (1 ):52–75. doi: 10.1007/s12325-020-01524-6 .33123967 31 Stauffer ME , Fan T . Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9 (1 ):e84943. doi: 10.1371/journal.pone.0084943 .24392162 32 Obrador GT , Macdougall IC . Effect of red cell transfusions on future kidney transplantation. Clin J Am Soc Nephrol. 2013;8 (5 ):852–60. doi: 10.2215/CJN.00020112 .23085723 33 Greeviroj P , Lertussavavivat T , Thongsricome T , Takkavatakarn K , Phannajit J , Avihingsanon Y , et al . The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis. J Nephrol. 2022;35 (9 ):2269–82. doi: 10.1007/s40620-022-01483-x .36383211 34 Kim IY , Kim JH , Kim MJ , Lee DW , Hwang CG , Han M , et al . Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease. Int Urol Nephrol. 2018;50 (12 ):2255–60. doi: 10.1007/s11255-018-1967-x .30136086 35 Wen Y , Xu L , Melchinger IA , Thiessen-Philbrook H , Moledina DG , Coca SG , et al . Longitudinal biomarkers and kidney disease progression after acute kidney injury. JCI Insight. 2023. doi: 10.1172/jci.insight.167731 .36951957 36 Karalliedde J , Fountoulakis N , Corcillo A , Maltese G , Flaquer M , Stathi D , et al . Effect of calcitriol treatment on arterial stiffness in people with type 2 diabetes and stage 3 chronic kidney disease. Br J Clin Pharmacol. 2023;89 (1 ):279–89. doi: 10.1111/bcp.15484 .35942813 37 Tanaka S , Kitamura H , Tsuruya K , Kitazono T , Nakano T , Group FKRSC. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study. Clin Exp Nephrol. 2022;26 (9 ):867–79. doi: 10.1007/s10157-022-02227-8 .35507237 38 Begum S , Latunde-Dada GO . Anemia of Inflammation with An Emphasis on Chronic Kidney Disease. Nutrients. 2019;11 (10 ). doi: 10.3390/nu11102424 .31614529 39 Weiss G , Ganz T , Goodnough LT . Anemia of inflammation. Blood. 2019;133 (1 ):40–50. doi: 10.1182/blood-2018-06-856500 .30401705 40 Baptista BG , Fanton S , Ribeiro M , Cardozo LF , Regis B , Alvarenga L , et al . The effect of Brazilian Green Propolis extract on inflammation in patients with chronic kidney disease on peritoneal dialysis: A randomised double-blind controlled clinical trial. Phytomedicine. 2023;114 :154731. doi: 10.1016/j.phymed.2023.154731 .36934668 41 Hao J , Huang X , Guan J , Feng J , Li D , Cao S , et al . Shenkang injection protects against renal fibrosis by reducing perforin expression through the STING/TBK1/IRF3 signaling pathways in natural killer cells. Phytomedicine. 2022;104 :154206. doi: 10.1016/j.phymed.2022.154206 .35724525 42 Tokuda K , Tanaka A , Tobe A , Shirai Y , Kurobe M , Kubota Y , et al . Impact of C-Reactive Protein on Long-Term Cardiac Events in Stable Coronary Artery Disease Patients with Chronic Kidney Disease. J Atheroscler Thromb. 2023. doi: 10.5551/jat.64047 .36908149 43 Chiang CK , Tanaka T , Inagi R , Fujita T , Nangaku M . Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest. 2011;91 (11 ):1564–71. doi: 10.1038/labinvest.2011.114 .21863063 44 Adelibieke Y , Shimizu H , Saito S , Mironova R , Niwa T . Indoxyl sulfate counteracts endothelial effects of erythropoietin through suppression of Akt phosphorylation. Circ J. 2013;77 (5 ):1326–36. doi: 10.1253/circj.cj-12-0884 .23337206 45 El-Agroudy AE , El-Baz A . Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients. Clin Exp Nephrol. 2010;14 (2 ):152–7. doi: 10.1007/s10157-009-0261-8 .20101431 46 Bhatraju PK , Robinson-Cohen C , Mikacenic C , Harju-Baker S , Dmyterko V , Slivinski NSJ , et al . Circulating levels of soluble Fas (sCD95) are associated with risk for development of a nonresolving acute kidney injury subphenotype. Crit Care. 2017;21 (1 ):217. doi: 10.1186/s13054-017-1807-x .28814331 47 Bosman DR , Winkler AS , Marsden JT , Macdougall IC , Watkins PJ . Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24 (3 ):495–9. doi: 10.2337/diacare.24.3.495 .11289474 48 Yang C , Meng Q , Wang H , Wang Y , Su Z , Liu L , Liu W , et al . Anemia and Kidney Function Decline among the Middle-Aged and Elderly in China: A Population-Based National Longitudinal Study. Biomed Res Int. 2020;2020 :2303541. doi: 10.1155/2020/2303541 .33083456 49 Chertow GM , Pergola PE , Farag YMK , Agarwal R , Arnold S , Bako G , et al . Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021;384 (17 ):1589–600. doi: 10.1056/NEJMoa2035938 .33913637 50 Zheng Q , Wang Y , Yang H , Sun L , Zhang P , Zhang X , et al . Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2022. doi: 10.1053/j.ajkd.2022.09.014 .36396085 51 Rosner MH , Reis T , Husain-Syed F , Vanholder R , Hutchison C , Stenvinkel P , et al . Classification of Uremic Toxins and Their Role in Kidney Failure. Clin J Am Soc Nephrol. 2021;16 (12 ):1918–28. doi: 10.2215/CJN.02660221 .34233920